Similarly, [64Cu]DOTA-trastuzumab visualized HER2-positive metastatic breast cancer with high precision thus providing valuable information for selection of patients that could benefit by HER2-targeted treatments [30,31]. This evidence concerns the gene ERBB2 and breast carcinoma.